OTC · Drug Manufacturers - Specialty & Generic

HUTCHMED (China) Limited (HMDCF) Stock

$2.16 +0.00% OTC: HMDCF Healthcare

HUTCHMED (China) Ltd. operates as a holding company, specializing in the research, development, manufacturing, and sales of both pharmaceutical products and health-focused consumer goods.

Valuation

MetricValue
Price$2.16
Market Cap$1.86B
P/E Ratio4.20
P/B Ratio18.52
P/S Ratio3.57
EPS (TTM)$0.51
52-Week High$3.82
52-Week Low$2.16
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE37.04%
ROA26.06%
ROCE-2.72%
Gross Margin11.64%
Operating Margin-7.14%
Net Margin83.30%
Debt/Equity0.08
Current Ratio4.96

Annual Financials (USD)

Metric20212022202320242025
Revenue$356.0M$426.0M$838.0M$630.0M$549.0M
Operating Profit$-343.0M$-413.0M$18.0M$-41.0M$-55.0M
Net Profit$-195.0M$-361.0M$101.0M$38.0M$458.0M
EPS$-0.24$-0.43$0.12$0.04$0.52
Op Margin-96.2%-96.9%2.2%-6.4%-9.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.4B$1.0B$1.3B$1.3B$1.8B
Total Liabilities$333.0M$393.0M$536.0M$502.0M$502.0M
Cash$378.0M$313.0M$284.0M$154.0M$71.0M
Borrowings$39.0M$27.0M$86.0M$90.0M$98.0M

Latest News

HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification GlobeNewswire · Jul 2, 2026 HUTCHMED to Announce 2026 Half-Year Financial Results GlobeNewswire · Jun 30, 2026 HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026 GlobeNewswire · Jun 25, 2026 HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress GlobeNewswire · Jun 12, 2026 Why HUTCHMED (China) Limited (HCM) Is Gaining Attention After China Biotech Re-Rating Insider Monkey · Jun 2, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-204.0M$-269.0M$219.0M$0$-65.0M
Investing Cash Flow$-323.0M$260.0M$-324.0M$-114.0M$-44.0M
Financing Cash Flow$-67.0M$-74.0M$-13.0M$-37.0M$0
Net Cash Flow$142.0M$-64.0M$-30.0M$-130.0M$-83.0M
Free Cash Flow$-221.0M$-305.0M$187.0M$-17.0M$-79.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-76.68
FCF Yield-4.03%
Quick Ratio4.83
Interest Coverage-18.33
Return 1Y-32.61%
Return 3Y-11.84%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
APNHFAspen Pharmacare Holdings Limited $8.80 +1.15% -33.17 $3.91B 1.36%
APNHYAspen Pharmacare Holdings Limited $8.59 -4.98% -33.17 $3.81B 1.40%
CHSYFChina Medical System Holdings Limited $1.57 +0.00% 17.84 $3.80B 2.55%
CURLFCuraleaf Holdings, Inc. $9.70 -2.07% -24.17 $2.56B 0.00%
DMPHFDermapharm Holding SE $53.00 +0.00% 16.91 $2.63B 1.91%

About HUTCHMED (China) Limited

HUTCHMED (China) Ltd. operates as a holding company, specializing in the research, development, manufacturing, and sales of both pharmaceutical products and health-focused consumer goods. The company's operations are divided into two main segments: Oncology/Immunology and Other Ventures. The Oncology/Immunology division is dedicated to the discovery, development, and commercialization of targeted therapies and immunotherapies aimed at treating cancer and immunological diseases. In contrast, the Other Ventures segment handles the company's other commercial activities, which include the marketing, production, and distribution of prescription medications and general healthcare products. Established on December 18, 2000, the company maintains its headquarters in Hong Kong.

HUTCHMED (China) Limited is headquartered in HK.

HUTCHMED (China) Limited (HMDCF) stock trades at $2.16 with a market capitalization of $1.86B. The stock is valued at a price-to-earnings (P/E) ratio of 4.20, price-to-book of 18.52, price-to-sales of 3.57. Over the past 52 weeks the stock has ranged between $2.16 and $3.82, and currently trades 43.5% below its 52-week high.

On profitability, HUTCHMED (China) Limited generates a return on equity (ROE) of 37.04% — well above the market average, a sign of a high-quality business, return on capital employed of -2.72%, an operating margin of -7.14%, a net profit margin of 83.30%.

Official website: www.hutch-med.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides